best online program for semaglutide Get a Prescription What you need to know
Description
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), particularly semaglutide, have emerged as potent therapeutic agents for both T2DM and obesity
The steelman argument against switching: A thoughtful clinician might argue against switching in the following scenario: a patient on Wegovy 2.4 mg has lost 12% of body weight over 6 months, tolerates the medication well, and has 8% more to lose to reach goal weight
If you experience a suspected side effect from retatrutide within a trial, this should be reported through the trial's pharmacovigilance process
Clinic hours vary
This means that you may have difficulty obtaining a supply of your medication or may not be able to get hold of it at all
The current advice is not to take Wegovy while breastfeeding
